Evidence map›Paper›PMID 37891733›Full record

ReviewBrain sciences2023

Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Yuchen Zhang, Jinzhou Tian, Jingnian Ni, Mingqing Wei, Ting Li, Jing Shi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuchen ZhangDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Jinzhou TianDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.ORCID 0000-0002-1607-5897
Jingnian NiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Mingqing WeiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Ting LiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Jing ShiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CN

Funding

Qihuang Scholar Foundation (China) Qihuang ScholarThe Fundamental Research Funds for the Central Universities 2019-JYB-TD-007The National Key Research and Development Program of China 2018YFC1704100The National Natural Science Foundation of China 82074362
6 · The paper itself

Abstract

The pathogenesis associated with Alzheimer's disease (AD) is particularly complicated, and early diagnosis and course monitoring of the disease are not ideal based on the available core biomarkers. As a biomarker closely related to neuroinflammation, YKL-40 provides a potential scalable approach in AD, but its association remains controversial and inconclusive with AD. We conducted this study to assess the utility of YKL-40 levels in peripheral blood and cerebrospinal fluid (CSF) of AD patients and healthy controls (HCs) by meta-analysis. We systematically searched and screened relevant trials for comparing YKL-40 levels between AD patients and HCs in PubMed, Embase, Cochrane, and Web of Science, with a search deadline of 14 March 2023 for each database. A total of 17 eligible and relevant studies involving 1811 subjects, including 949 AD patients and 862 HCs, were included. The results showed that YKL-40 levels in the peripheral blood of AD patients and HCs did not possess significant differences. Subgroup analysis showed YKL-40 significantly differed in plasma (SMD = 0.527, 95%CI: [0.302, 0.752];

Indexed as

Alzheimer’s diseasebiomarkersbloodcerebrospinal fluidmeta-analysisYKL-40

Identifiers

PMID37891733
PMCPMC10605482
OpenAlexW4386995638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.